The FDA has approved Massachusetts-based TheraCos Bio’s type 2 diabetes drug Brenzavvy. The drug was first approved for cats with diabetes back in December. Hear more about the SGLT2 inhibitor, including the impressive amount of clinical data that its approval was based on, and the stiff market competition it will be facing.

Register for our free featured webinar here: The Benefits of Digital Pathology with Automated Quality Control for Accelerating Drug Discovery - https://xtalks.com/webinars/the-benefits-of-digital-pathology-with-automated-quality-control-for-accelerating-drug-discovery/

Read more on this story here: New Type 2 Diabetes Drug Brenzavvy Wins FDA Approval - https://xtalks.com/new-type-2-diabetes-drug-brenzavvy-wins-fda-approval-3351/

Receive weekly news and webinar updates right in your inbox: https://xtalks.com/register/

Listen live and interact with featured speakers on our upcoming Life Science webinars: https://bit.ly/2YRzAV0

#fda #Brenzavvy #diabetes